Biocytogen
Biocytogen is a global biotech company that drives the discovery of fully human monoclonal, bispecific, multispecific, ADC, VHH, and TCR-mimic antibodies across 1,000+ druggable targets, providing 1M+ authentic antibody sequences through its RenBiologics™ sub-brand for partnerships.
Biocytogen is advancing antibody drug development through innovative technologies. Leveraging gene-editing expertise, it pioneered drug target knock-in humanised models and offers 4,000+ models via BioMice™, along with in vivo, ex vivo, and in vitro pharmacology and custom gene-editing services.
